Showing results (951-960 of 1,194) with videos related to
Sort By:
Pageof 120
Science (New York, N.Y.)|May 1, 2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, et al.Nature Communications|December 22, 2018
Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cellsHugh S Gannon, Tao Zou, Michael K Kiessling, et al.Oncogene|February 22, 2007
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272Y Minami, T Shimamura, K Shah, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.The International Journal on Drug Policy|April 6, 2025
Recruiting opioid treatment program administrators for a national survey: Outcomes and lessons learnedBenjamin R Brady, Beth E Meyerson, Alissa Davis, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2024
Human Disease due to Mycobacterium bovis Linked to Free-Ranging Deer in MichiganJames Sunstrum, Laura E Power, Helene M Fligiel, et al.Blood|June 4, 2010
Recurrent BRAF mutations in Langerhans cell histiocytosisGayane Badalian-Very, Jo-Anne Vergilio, Barbara A Degar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman, Beow Y Yeap, Neal I Lindeman, et al.Angewandte Chemie (International Ed. in English)|November 22, 2013
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitorSang Min Lim, Kenneth D Westover, Scott B Ficarro, et al.Cancer Research|June 22, 2013
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaRachel G Liao, Joonil Jung, Jeremy Tchaicha, et al.Pageof 120